CXCL12 and cancer: Preclinical mechanistic studies as well as translational and clinical evaluation of the role of the SDF-1/CXCR4 axis in the context of cancer radiotherapy and immunotherapy might lead to novel treatment strategies implementing SDF-1/CXCR4 targeting in this context using the small molecule inhibitors already approved for the use in patients and healthy donors for HSC mobilization.